Team Introductions: CML Experts From UT Southwestern vs. Mayo Clinic

Now Viewing

EP: 1.Team Introductions: CML Experts From UT Southwestern vs. Mayo Clinic

EP: 2.Chronic-Phase CML: The OPTIC Study

EP: 3.Cross Q&A: Ponatinib Dosing in Relapsed/Refractory Chronic-Phase CML

EP: 4.Chronic Myeloid Leukemia: Retrospective Analysis of the PACE Study

EP: 5.Cross Q&A: Arterial Occlusive Events With Ponatinib in the PACE Trial

EP: 6.Olverembatinib Study in Patients With Heavily Pretreated Chronic Myeloid Leukemia

EP: 7.Cross Q&A: Role of Olverembatinib in Heavily Pretreated CML

EP: 8.Chronic Myeloid Leukemia: Long-Term Follow-up of Low-Dose Dasatinib

EP: 9.Cross Q&A: Real-World Use of Low-Dose Dasatinib in CML

EP: 10.Mayo Clinic and UT Southwestern “Face Off” Over Multiple Myeloma and CML

Transcript:

Judy Schreiber, PhD, RN: Good morning and welcome to the CancerNetwork®’s Face-Off. Today we’re focusing on multiple myeloma and chronic myeloid leukemia [CML]. My name is Judy Schreiber, and I’m today’s program’s host. First and foremost, I’d like to thank the supporters of today’s program, which is Takeda [Pharmaceutical]. We thank you very much. We couldn’t be here without your support, and it’s greatly appreciated. A bit about this program, Face-Off is a series that is a little different than many of the educational programs or events you’ve seen in the past. But make no mistake, it’s educational at its core, but designed to be fun. What makes Face-Off different from other educational events is the fact that it’s not just a presentation, but it’s much more than that; this is a competition. Here in Rochester, Minnesota, we have the visiting team of University of Texas Southwestern, captained by Dr Larry Anderson, and the home team of the Mayo Clinic, with Dr[Prashant] Kapoorand Dr[Kebede] Begna.

They are not just presenting data to you, but also to each other, and they’ll be questioning each other. So how does it work? The visiting team in Texas will lead off since the visiting team always goes first. They’ll present several studies to the home team, after which the home team will have the opportunity to challenge the visiting team. There’ll be Q&As [question and answer sessions] after each presentation. The presenter should make sure [their] presentation [has a] level of enthusiasm or levity. At the end of each question and answer session, we’ll have questions from the fans if possible. Otherwise, we’ll have polling questions at the end of all of the multiple myeloma presentations, and then at the end of the CML presentations. Not only that, but CancerNetwork® will be donating a starting amount of $2000 toward your institution for the winners, [which is] your institution’s travel fund for participating in the program, but also an additional $1000 for the winner.

We’d like to extend an invitation to you and your colleagues to join us and cheer us on as CancerNetwork® will donate an additional $250 per live audience member that will help toward accumulating the final voting tallies. At this time, I’d like to introduce the captains of today’s teams. Dr Anderson, representing the visiting team, if you [could please] introduce your team.

Larry Anderson Jr, MD, PhD, FACP: Hi, I’m Dr. Larry Anderson, director of the myeloma, Waldenstrom, and amyloidosis program at UT Southwestern [Medical Center, Dallas]. This is Dr Adeel Khan of the myeloma program at UT Southwestern.

Judy Schreiber, PhD, RN: For Mayo, Dr Kapoor and Dr Begna, if you can introduce your teams.

Prashant Kapoor, MD, FACP: Hi, I’m Prashant Kapoor from Mayo Clinic, Rochester, [Minnesota]. I belong to the dysproteinemia, myeloma, and amyloidosis disease group. I’m joined here on the myeloma team by my colleague, Dr Wilson Gonsalves, also from the same group.

Kebede Begna, MD: Hi, my name is Kebede Begna. I am [from] the acute leukemia and myeloid neoplasm disease group. I’m here with my colleague, Dr Abhishek Mangaonkar, from the same group. We also are a CML clinic. Thank you.

Transcript edited for clarity.